News | May 12, 2022
Suven Pharmaceuticals - CDMO core growth intact; formulations to pick up
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Cipla has reported consolidated financial results for the period ended March 31, 2022
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
The new building is expected to be commissioned by 2024. Post the expansion, Nanavati-Max Hospital will be amongst the largest private sector hospital in western India
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
He was previously working as the CEO of IVD business at Trivitron Healthcare and drove its growth through innovation
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
The increase in PAT is driven by higher sales and lower marketing and depreciation charge vs the same period last year
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Subscribe To Our Newsletter & Stay Updated
